Meta Description: 
In this webinar, we will be discussing what must be taken into consideration to unlock the importance of urine as a source for biomarker discovery.
webinar science biology biotechnology masterclass master class

Paving the Path for

NGS-Based

Biomarker Discovery

Webinar with LIVE Q&A

June 16, 2022

View more masterclass webinars

On Demand

Liquid Biopsies: | Paving the Path for NGS-Based Biomarker Discovery

45 min + Q&A

10:30 AM (EDT)
Register
1:30 PM (EDT)
Register

Featured Speaker

Speakers:
Mohamed El-Mogy, M.Sc, Ph.D - Director of R&D Services
Michelle Stopher - Key Account Manager

Key Learning Objectives

  1. The advantages of liquid biopsies as a biospecimen for disease detection & monitoring
  2. The composition of liquid biopsy samples and the importance of each analyte
  3. Current Next Generation Sequencing (NGS) applications driving translational clinical research
  4. A spotlight on Small RNA-Seq as an application for biomarker discovery
  5. Emerging RNA-Seq applications for transcriptomics from liquid biopsies & the challenges
  6. Stay tuned for ‘Making Sense of your NGS Data’ webinar’ coming Fall 2022

Abstract

Liquid biopsy samples are increasingly becoming one of the most valuable, minimally-invasive sources of information as the basis of diagnosis and disease monitoring as well as disease prevention. Biospecimens such as plasma, serum and urine contain various biomarkers that provide key insights into changes within the genome, epigenome, transcriptome and proteome of a patient. Next Generation Sequencing (NGS) is an extraordinary tool enabling researchers to dive deeper into the contents of liquid biopsy samples to advance discoveries in the fields of cancer research and complex disease genomics. In this webinar, we will discuss the various Next Generation Sequencing applications that can be explored which allow researchers to analyze the circulating analytes contained within liquid biopsy samples. We will focus a spotlight on Small (micro) RNA-Sequencing from cell-free RNA and RNA derived from exosomes, as an application for biomarker discovery and understanding cell to cell communication. We will also discuss the emerging field of transcriptome sequencing from cell-free RNA in liquid biopsy samples, the challenges of library preparation, and the immense potential of profiling circulating transcripts.

Iva Laska and Nikola Breberina

About the speakers

Dr. Mohamed El-Mogy is the Director of R&D Services at Norgen Biotek and has been with Norgen for over 12 years. Dr. El-Mogy’s background is in cell and molecular biology with an extensive focus in sample preparation and NGS applications. He oversees Norgen’s Research and Development pipelines and also acts as a Senior Research Scientist for Norgen’s Next Generation Sequencing and Molecular Diagnostic Services. Dr. El-Mogy plays an instrumental role in the continual evolution of Norgen’s laboratory services and advancements in science.

Michelle is a Key Account Manager for Norgen’s Next Generation Sequencing Services and has been working closely with some of the largest, most influential research institutions and companies for over 5 years at Norgen. Michelle holds an Honours Bachelor Science in Cell and Molecular Biology from University of Toronto and her experience lends to her extensive knowledge of Norgen’s liquid biopsy portfolio. She strives to ensure that Norgen provides comprehensive NGS solutions for even the most challenging of sample types.

Be the first to know about upcoming webinars

We are excited to offer new webinars in our MasterClass series. Sign up to be the first to get all of the details!


Sign up now
MasterClass webinar sign up stay up to date
×

SARS-CoV-2, The Flu and You

The Importance of Multiplex Detection and the Fourth Wave

The COVID-19 pandemic has taught us the value of early detection and mass testing initiatives to prevent viral spread. As we strive to get back to "normal", what does the 2021/22 Flu Season hold for us? Public Health Agencies are calling for better testing methods that can detect and differentiate COVID-19 and Influenza. Join the Team at Norgen Biotek Corp. for our first MasterClass on October 7th, 10am EDT, where we will compare Influenza and COVID-19 and how they differ, better understand the similarities between them and discuss new and emerging methods for multiplex detection of both viruses. We will also look at the progression of COVID-19 detection assays and how it relates to how we are handling the fourth wave.

49 min (Q&A included)

Featured Speaker:

Speaker: Jaclyn Ugulini, B.Sc. - Sales & Marketing Manager
×

Urine Exosomes

Top 6 Strategies in Sample Handling

Urine has been steadily gaining popularity as a powerful tool for biomarker discovery as it is easy to collect, non-invasive and available in large quantities. More recently, exosomes have also been identified in urine and its inherent genetic material has proved to reflect an abundant amount of information related to an individual's pathophysiology. Traditional methods of sample handling are simply not robust enough for the molecular analysis required within precision medicine today. Since human urine is one of the most important fluids providing useful information about the body condition, appropriate pre-analytical techniques become critical towards its use within clinical and profiling applications. We discuss the top 6 strategies in sample handling and purification techniques that will lend itself towards the development of a standardized protocol and ultimately, a clean sample fit for investigation.

65 min (Q&A included)

Featured Speaker:

Speaker: Iva Laska- Senior Life Science Product Specialist
×

Exosomes

Everything You Need to Know About Exosomes | From Purification to Disease Monitoring

An accumulation of evidence has shown that exosomes and other extracellular vesicles (EVs) complete cell-to-cell communication by transmitting information to different cells throughout the human body. However, the function and/or physiology of cells can actually be altered upon the transmission of the exosomal contents to a distant or neighbouring cell. Recent research has identified the presence of specific microRNA (miRNA) signatures within exosomes that are related to specific diseases and can be used as biomarkers. Exosomal miRNA profiles have been found to vary significantly depending on the purification or isolation methods used. Therefore, in order to create a reliable RNA profile that could be used as a biomarker, exosome purification and isolation techniques must be taken into consideration since exosomes mainly contain low concentrations of miRNA

82 min (Q&A included)

Featured Speaker:

Speaker: Dr. Abdalla, MSc, PhD - Senior Research Scientist
Moderator: Alexandra White - Life Sciences Product Specialist
Register to download package Download Package
×

Plasma/Serum Cell-Free Nucleic Acids

Understanding the Basics and Applications of Plasma/Serum cf-DNA and cf-RNA

Cell-free DNA (cf-DNA) and cell-free RNA (cf-RNA) are considered important biomarkers in plasma and serum for the detection of several diseases and conditions. These cf-DNA and cf- RNA are generally released in the bloodstream as the cells undergo apoptosis or necrosis. The cf-DNA and cf-RNA levels alter as per the underlying physiological processes, which might be driven by a disease or a condition. This is the basis of the non-invasive diagnosis and disease monitoring as well as disease prevention. The accurate detection of the cf-DNA/cf-RNA content in plasma/serum is influenced by the procedures implemented in the purification of cf-DNA/cf- RNA. In this webinar, we will discuss the different types of collection devices available to separate and preserve plasma/serum from blood. We will also discuss how different chemistries may affect cf-DNA/cf-RNA profiles. The webinar will also focus on cf-DNA/cf-RNA analysis methodologies and how these molecules can be exploited to generate data from instruments as simple as Qubit to as sophisticated as Next Generation Sequencing.

45 min

Featured Speaker:

Alex Chauhan, M.Sc, Ph.D. - Research Scientist
Moderator: Alexandra White - Life Sciences Product Specialist
Register to download package Download Package
×

Unlocking the Importance of Urine Biomarkers

From Discovery to Diagnosis

The search for minimally invasive methods for the early detection of diseases is on the rise. In particular, the search for biomarkers among different diseases is showing promise as they have been successfully used within clinical settings for the early detection and monitoring of some cancers. While blood and tissue biopsy samples are commonly used within cancer research for biomarker discovery, urine is gaining considerable interest as an alternative sample type for that purpose. Circulating nucleic acids from both normal and cancer cells have been found in urine, which makes it an excellent sample source for the discovery of cancer-specific biomarkers. Recent evidence has exhibited a plethora of information that can be obtained from urine for the early detection of different cancer types, regardless of their location. Because of the nature and the origin of circulating nucleic acid, different cell-free DNA and cell-free RNA signatures have been identified in urine. Such differences are highly attributed to different factors, including the means of sample collection and the purification method used. In this webinar, we will be discussing what must be taken into consideration to unlock the importance of urine as a source for biomarker discovery.

29 min

Featured Speaker:

Michelle Stopher - NGS Key Account Manager
Moderator: Nikola Breberina - Life Sciences Product Specialist
Register to download package Q&A
Download Package
×

A Multi-Omics Look Into the Stool Microbiome

Stool Microbiome

The gastrointestinal (GI) tract is an integral system to humans and animals, but it does more beyond breaking food down, absorption, and waste excretion. The GI tract is inhabited with microbes with significant relationships to the host. The gut microbiome plays an integral role in pathologies, immunity, nutrition, metabolism, and has been connected with brain function. Another member of this region is the gut virome - consisting of bacteriophages, host viruses, and transient viruses - which plays a role that is not yet well defined. Host DNA is also shed in the GI tract and can be used as biomarkers for some host diseases. Invasive methods can provide an accurate description of the gut environment; however, these methods are not sustainable. Luckily, a snapshot of the gut activity can be obtained via a non-invasive sample type. Feces collected from the host is widely accepted and studied as a proxy for the gut. In this webinar, we will discuss different fecal collection and storage methods and delve into the information available from feces. The webinar will also explore the wide range of applications for this sample.

41 min

Featured Speaker:

Jason Byron Perez, M.Sc. - Senior Product Specialist
Moderator: Lea Milkin - Life Sciences Product Specialist